Navigation Links
Biomarkers: Discovery Techniques and Applications - A Global Market Overview
Date:11/14/2013

developing drugs and biomarkers would be associated with identifying that section of the population that would garner the maximum benefit from that drug treatment. Developing such biomarkers requires expending considerable efforts and resources, which would enable in expanding the tasks accomplished by biomarkers in disease screening as surrogate endpoints and diagnostic indices.

Biomarker discovery techniques analyzed in this report include Bioimaging, Bioinformatics and Omics Technologies. On a broader geographic level, these technologies further drilled down to Bioimaging – Computed Tomography (CT), Magnetic Resonence Imaging (MRI), Ultrasound and Other; and Omics Technologies – Genomics, Metabolomics, Proteomics and Other. The study also explores the global market for therapeutic areas of biomarkers comprising Cardiology, Neurology, Oncology and Other.

The report reviews, analyses and projects the Biomarkers market for global and the regional markets including the United States, Europe, Asia-Pacific and Rest of World. The regional markets further analyzed for 10 independent countries across Europe – France, Germany, Italy, Spain, Sweden, the United Kingdom; and Asia-Pacific – Australia, China, India and Japan. Accounting for a lion's share of an estimated 47% in 2013, equating to US$18.9 billion, the United States leads the global market for Biomarkers. Growing at a robust compounded annual growth rate of 18.8% during the period 2013-2020, the global market is projected to touch US$63.2 billion.

This 350 pages, global market report includes 100 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. The statistical tables represent the data for the market value in US$ by geographic region, biomarker discovery techniques and therapeutic area. This report profiles 52 key global players and 70 major players a
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Biomarkers: Technological and Commercial Outlook 2013-2023
2. Biomarkers: Technological and Commercial Outlook 2012-2022
3. Discovery Labs Reports Third Quarter 2013 Financial Results
4. Novartis: Layoffs as a Sign of Productivity Crisis in R&D; The CBCD Offers New Technology to Aid in Drug Discovery
5. Discovery Labs to Host Conference Call to Discuss Third Quarter 2013 Results on Wednesday, November 13, 2013
6. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
7. Discovery Labs Announces Completion of $50 Million Public Offering
8. Discovery Labs Prices $50 Million Public Offering of Common Stock
9. Discovery Labs Announces Proposed Public Offering of Common Stock
10. Productivity Crisis in Pharmaceutical Industry Increases Drug Prices; The CBCD Offers New Technology to Aid in Drug Discovery
11. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company, is pleased to announce that the final ... have been locked.  Prototypes for industrial and regulatory ... an application for CE mark clearance to market ... in 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized ... The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Industries’ (BI) advanced cell culture products, announces the availability of BI’s line of ... by Biological Industries, these stem cell differentiation media offer a complete system for ...
(Date:7/28/2015)... 29, 2015 A ... rapidly developing and commercialising innovative medicines to transform ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality ... c. £76.5m), gross, from blue chip institutional investors and ...
Breaking Biology Technology:RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11
... , HOLDEN, Mass., Sept. 14 ... Elkan Gamzu, Ph.D. as Chairman to its Board of ... pharmaceutical and biotechnology experience and has held senior executive ... Project Management at Millenium Pharmaceuticals, CEO of Cambridge Neuroscience, ...
... , , , ... Incorporated (Nasdaq: GPRO ) announced today that it is spinning ... developing rapid, highly accurate molecular assays for biopharmaceutical production, water and food ... will own 19.9% of the new company, Roka Bioscience, Inc. Affiliates ...
... , , ... RAPS (Regulatory Affairs Professionals Society) conference in booth #607, ... comply with an increasingly complex web of regulations governing ... pharmaceutical and biotechnology companies--is used to organize, send and ...
Cached Biology Technology:Elkan Gamzu, Ph.D. Joins Hygeia Therapeutics' Board of Directors as Chair 2Gen-Probe to Consolidate Industrial Assets Into New, Independent Company 2Gen-Probe to Consolidate Industrial Assets Into New, Independent Company 3Gen-Probe to Consolidate Industrial Assets Into New, Independent Company 4Prolifiq Announces Software for Life Sciences: Accelerates Sales, Embeds Adherence to Regulatory Compliance, Incorporates Good Promotional Practices 2Prolifiq Announces Software for Life Sciences: Accelerates Sales, Embeds Adherence to Regulatory Compliance, Incorporates Good Promotional Practices 3
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... energy needs from biomass sources, including household waste, agricultural residues ... from the Tyndall Centre for Climate Change Research at The ... to 44% of its energy by these means without the ... Policy journal, highlights the country,s potential abundance of biomass ...
... February 19Researchers from the Franciscan University of Steubenville, Ohio ... seizures. They determined that diet could influence susceptibility to ... that could be useful in treating disorders such as ... behind the experiment, and his lab made the connection ...
... a tiny floating plant that,s been known to drive people ... that often becomes a hard-to-control weed in ponds and small ... and as a source to produce pharmaceuticals. Now, the genome ... miniscule plant,s potential as a biofuel source a big boost. ...
Cached Biology News:UK failing to harness its bioenergy potential 2Could metabolism play a role in epilepsy? 2Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Biology Products: